NYSE president says the appeal of the public market has ‘never been more alive and well’

NYSE president says the appeal of the public market has ‘never been more alive and well’


Companies are eager to go public but are holding back due to the uncertainty in the market, NYSE President Lynn Martin told CNBC’s Jim Cramer on Monday.

“It’s on pause. The reason it’s on pause is because of all the volatility that you see in the market. But you know, the companies that I talk to, those companies who are private, the public market currency has never been more alive and well,” Martin said in an interview on “Mad Money.”

The number of global IPOs, or initial public offerings, declined 54% in the second quarter year-over-year, according to a report from EY. The Americas region saw the biggest drop with a 73% decrease in deals.

U.S. stocks have seesawed this year as skyrocketing inflation, the Federal Reserve’s interest rate increases and the Russia-Ukraine war have led investors to sell holdings. Wall Street is now looking to the Fed’s meeting this week, which many investors expect will lead to a 75 basis point rate increase.

Martin said that the lull in public listings is indicative of the current market environment, not the companies’ willingness to gain new shareholders.

“They want to use that public market currency to grow their business, invest in R&D, acquire new businesses, take their businesses in directions that they can’t even fathom right now. But they’re not going to do it in a period when there’s tremendous volatility in the market,” she said.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer Twitter – Facebook – Instagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]





Source

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More
Disney embarks on new chapter as Josh D’Amaro takes over as CEO
Business

Disney embarks on new chapter as Josh D’Amaro takes over as CEO

Larissa Manoela and Josh D’Amaro, Chairperson of Walt Disney Parks and Resorts, wave to the audience after Panel Disney Experiences during Day 2 of the D23 Brazil: A Disney Experience at Transamerica Expo Center on November 09, 2024 in Sao Paulo, Brazil. Ricardo Moreira | Getty Images Disney is turning the page on a new […]

Read More